Viking Therapeutics presents data on amylin and calcitonin receptors

Viking Therapeutics announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association. The presentation highlights the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide. The studies were summarized in a poster presentation at the annual scientific conference of the American Diabetes Association, being held June 21-24, 2024, in Orlando, Florida. The study results demonstrate that Viking’s series of dual amylin and calcitonin receptor agonists reduced food intake in lean rats in the period from 0-72 hours following a single subcutaneous dosing. At 72 hours following a single subcutaneous dose, Viking’s novel compounds resulted in up to 8% body weight reductions compared to vehicle-treated animals. In a DIO mouse model, treatment with Viking’s series of co-agonists for 24 days resulted in body weight reductions that were comparable to those achieved in cagrilintide-treated animals. Additionally, improvements in key metabolic markers, including blood glucose levels, were observed in DIO mice treated with the company’s compounds for the 24-day time period.